Dataset Information


Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

ABSTRACT: Background:We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer. The clinical validity of this finding in independent studies, among patients receiving different chemotherapy, is unknown. Patients and methods:The ARTemis trial randomly assigned 800 women with early stage breast cancer between May 2009 and January 2013 to three cycles of docetaxel, followed by three cycles of fluorouracil, epirubicin and cyclophosphamide once every 21 days with or without four cycles of bevacizumab. The primary endpoint was pCR (absence of invasive cancer in the breast and lymph nodes). We quantified lymphocyte density within haematoxylin and eosin (H&E) whole slide images using our previously described computational pathology approach: for every detected lymphocyte the average distance to the nearest 50 lymphocytes was calculated and the density derived from this statistic. We analyzed both pre-treatment biopsies and post-treatment surgical samples of the tumour bed. Results:Of the 781 patients originally included in the primary endpoint analysis of the trial, 609 (78%) were included for baseline lymphocyte density analyses and a subset of 383 (49% of 781) for analyses of change in lymphocyte density. The main reason for loss of patients was the availability of digitized whole slide images. Pre-treatment lymphocyte density modelled as a continuous variable was associated with pCR on univariate analysis (odds ratio [OR], 2.92; 95% CI, 1.78-4.85; P?


PROVIDER: S-EPMC5834010 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4755003 | BioStudies
2014-01-01 | S-EPMC4252785 | BioStudies
2017-01-01 | S-EPMC5834079 | BioStudies
2020-01-01 | S-EPMC7606448 | BioStudies
2013-01-01 | S-EPMC3726421 | BioStudies
1000-01-01 | S-EPMC5398384 | BioStudies
2019-01-01 | S-EPMC6692690 | BioStudies
2020-01-01 | S-EPMC7113135 | BioStudies
2020-01-01 | S-EPMC7254668 | BioStudies
1000-01-01 | S-EPMC3825616 | BioStudies